CUE Insider Trading

Cue Biopharma, Inc. (CUE) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $142.2M, listed on NASDAQ, employing roughly 29 people, carrying a beta of 2.63 to the broader market. Cue Biopharma, Inc. Led by Shao-Lee Lin, public since 2018-01-02.

In the last 12 months, Cue Biopharma, Inc. insiders made 7 buy transactions and 15 sale transactions.

DateNameTypeSharesPriceValue
Oct 14, 2026Ray SumitaS-Sale1,844$28.05$51.7K
Oct 14, 2026Meluzio Michael VincentS-Sale1,144$28.05$32.1K
Oct 14, 2026Lin Shao-LeeS-Sale10,000$27.50$275.0K
Oct 14, 2026Lin Shao-LeeS-Sale1,087$28.05$30.5K
Aug 28, 2026Sarraf PashaA-Award18,400$0.00$0
Aug 28, 2026Garzone PamelaA-Award18,900$0.00$0
Aug 17, 2026Ray SumitaM-Exempt18,196$0.00$0
Aug 17, 2026Ray SumitaS-Sale2,383$29.37$70.0K
Aug 17, 2026Ray SumitaS-Sale6,442$30.35$195.5K
Aug 17, 2026Ray SumitaS-Sale4$31.13$125

CUE Insider Activity by Quarter

Reported Form 4 and Form 5 lines under CUE's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Dec 29, 2017, and a quarter counts only when every filing for it was read.

QuarterPurchasesBoughtSalesSoldOther Lines
Q4 2026 (so far)0N/A4$389.3K0
Q3 20260N/A11$2.0M21
Q2 20260N/A0N/A11
Q1 20260N/A0N/A6
Q4 20255$99.7K0N/A1
Q3 20250N/A0N/A4
Q2 20250N/A0N/A1
Q1 20250N/A0N/A12
Q4 20241$30.9K0N/A1

CUE Institutional Ownership (13F)

As of Jun 30, 2026 (Q2 2026), 49 institutions reported holding 1,641,351 CUE shares, valued at $51.8M as reported, 42.4% of its market cap (market cap of Jun 26, 2026). 1 of them reported some or all of their shares on another basis (before a reverse split, or as ADRs): they are in the institutions and the value, those shares not in the shares. That is -7 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 14 opened a position, 21 closed one, 20 added and 11 trimmed.

Top Holders, Q2 2026

ManagerSharesValueChange
Bleichroeder LP370,682$11.7M+143,377
Driehaus Capital Management LLC292,144$9.2MNew
VANGUARD CAPITAL MANAGEMENT LLC161,700$5.1M+79,785
Ikarian Capital, LLC104,364$3.3MNew
Tetragon Partners GP Ltd93,819$3.0MNew
STEMPOINT CAPITAL LP66,995$2.1MNew
BlackRock, Inc.57,807$1.8M+42,835
ADAR1 Capital Management, LLC55,193$1.7MNew
Lion Point Capital, LP52,928$1.7M-20,500
Squadron Capital Management LLC50,000$1.6MNew

By Quarter

QuarterInstitutionsSharesValue
Q2 2026*491,641,351$51.8M
Q1 20265621,389,020$4.9M
Q4 20254821,788,520$6.7M
Q3 20255218,059,864$13.0M
Q2 20254717,351,745$11.9M
Q1 20254911,402,706$10.4M
Q4 20245511,759,494$12.8M
Q3 20245013,911,295$10.5M
Q2 20247513,930,983$17.3M

* Q2 2026: 1 with shares on another basis (not in the shares).

From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.

ETFs Holding CUE

FundWeight of CUEShares (as reported)Value (as reported)Source updated
VTI Vanguard Morningstar Total Stock Market ETF0.00%111,867$2.9MOct 7, 2026
VXF Vanguard Extended Market ETF0.00%47,090$1.2MOct 7, 2026
IWC iShares Micro-Cap ETF0.01%8,638$194.4KOct 8, 2026
AVSC Avantis U.S. Small Cap Equity ETF0.00%301$6.8KOct 8, 2026
AVTM Avantis Total Equity Markets ETF 10.00%10$225Oct 8, 2026

From each fund's latest holdings file on record that shows CUE's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as CUE's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for CUE reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is CUE's share of that fund.

How to Read CUE Insider Activity

Net insider sentiment skews to the sell side over the trailing twelve months: 15 sales versus 7 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →

Frequently asked CUE insider trading questions

How active are CUE insiders right now?
Over the trailing twelve months, Cue Biopharma, Inc. (CUE) insiders made 7 buy transactions and 15 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (15 sales vs 7 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
What counts as an insider transaction?
Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
Are CUE insider buys a bullish signal?
Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
How do CUE insider transactions affect options pricing?
Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.